PALA (NSC-224131) in advanced carcinoma of the cervix. A phase II study of the Gynecologic Oncology Group.

@article{Muss1984PALAI,
  title={PALA (NSC-224131) in advanced carcinoma of the cervix. A phase II study of the Gynecologic Oncology Group.},
  author={Hyman Bernard Muss and Brian N. Bundy and Philip John Disaia and Frederick B. Stehman and Jackson Beecham},
  journal={American journal of clinical oncology},
  year={1984},
  volume={7 6},
  pages={741-4}
}
Thirty-six patients with advanced carcinoma of the cervix received PALA at a dosage of 5 gm/m2 every three weeks. Thirty-three patients had received prior irradiation therapy and chemotherapy. No complete or partial responses were seen. The major toxicity was dermatologic and occurred in 16/36 (44%) of patients. Three patients experienced dose limiting disorientation or confusion. PALA was not associated with any antitumor activity in patients with advanced carcinoma of the cervix who had… CONTINUE READING